Onco Actu du 23 novembre 2016

	3.1 Tabac
Australia’s plain cigarette packs are ‘putting teens off smoking’ [Cancer Research UK] An Australian study, published in the Journal of Tobacco Control, found that almost a third of teens (31%) who tried smoking or who had previously smoked said plain packs made them less likely to smoke again.
	4. Dépistage, diagnostic et pronostic
UK’s pathology services at tipping point [Cancer Research UK] "The UK’s cancer survival is lagging behind other European countries and improving early diagnosis through diagnostic services is one of the ways to address this. The diagnostic bottleneck will only get worse without action now and this involves addressing staff shortages in imaging, endoscopy and pathology.”
Device Uses Cancer Cells' Mass to Predict Response to Treatment [NCI] As each cell passes repeatedly through the device, its change in mass over a period of several minutes (called mass accumulation rate, or MAR) is also calculated.
NHS cancer testing service 'at breaking point' [BBC News] Without more staff to meet the demand, long waits for test results could become the norm, says the charity.
NHS 'struggling to cope' with increase in people undergoing cancer tests [The Guardian] NHS pathology services cannot keep up with growing number of biopsies and blood samples, Cancer Research UK report says.
	5. Traitements
New era in cancer treatment to begin as Sadiq Khan opens revolutionary radiotherapy machine [Institute of Cancer Research] The MR Linac machine is the first technology to simultaneously generate magnetic resonance images and deliver X-rays — allowing radiotherapy to be adjusted in real time and delivered more accurately and effectively than ever before.
Restoring leaky blood vessels could lead to new cancer treatment [Cancer Research UK] By slowing down the rate that cells lining the blood vessels could burn sugar, the scientists could 'cool down' their overheated engines to create more healthy and structured blood vessels, according to the study published in the scientific journal Cancer Cell.
	5.2 Pharma
FDA lifts PD-L1 hold on AstraZeneca head and neck cancer test [FierceBiotech] Durvalumab, which won breakthrough therapy designation from the FDA to treat urothelial bladder cancer in February, has suffered several trial setbacks, and a few weeks back AZ said it was scrapping plans to get an early FDA nod for the drug as a second-line HNSCC option.
After a painful stumble, AstraZeneca gets top checkpoint cancer program back on track [EndPoints] Resuming enrollment, though, isn’t just a matter of hanging an ‘open’ sign out in front of the clinic.
	5.2.3 Pharma - économie
Nonadherence costs pharma $600B-plus in annual sales: study [FiercePharma] There's a downside to pushing adherence that may be holding some pharma companies back. That’s the perception of drug “pushing,” with some critics suggesting that adherence programs are being used as marketing tools to get patients to fill and refill prescriptions.
	5.3 Traitements - FDA, EMA, NICE...
Could the FDA be dismantled under Trump? [STAT] For Trump and his advisers, including Newt Gingrich, the agency has for too long acted as a barrier to medical innovation.
	5.3.4 Traitements - AMM (FDA, EMA)
European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin [BMS] This milestone marks the sixth EU approval for Opdivo in four distinct cancer types in less than two years.
	5.4 Traitements - Economie
Precision medicine will increase drug prices and that’s a good thing [MedCity News] Fewer people will be treated with a given drug, compared to standard therapies, but everyone is better off – the treated have better outcomes, and everyone else can move on to another therapy that works for them. In a world where prices are increasingly based on value, this means that drug prices are likely to rise, but overall spending on pharmaceuticals may not change, or could actually fall.
	5.8.1 ASH - Communiqués
New KEYTRUDA® (pembrolizumab) Data in Blood Cancers to be Presented at 58th Annual Meeting of the American Society of Hematology [Merck] Updated Findings with Longer Follow-Up in Classical Hodgkin Lymphoma to be Featured in Oral Presentations.
Nearly 350 Abstracts Evaluating Celgene Therapies to Be Presented at American Society of Hematology Annual Meeting (ASH) [Celgene] Presentations will focus on a wide range of disease areas including multiple myeloma, lymphoma, leukemia, myelodysplastic syndromes and beta-thalassemia.
	6. Lutte contre les cancers
William Sellers appointed to faculty at Broad Institute, Dana-Farber Cancer Institute, and Harvard Medical School [Broad Institute] Cancer genomics and therapeutics expert returns to academia after decade in industry.
	6.1 Observation
Palliative care linked to better, if not longer, life [Reuters] For the current study, researchers examined data from 43 previously published studies with a total of almost 13,000 patients and 2,500 caregivers to see if a pooled analysis could offer a clearer picture
	6.10.1 Politiques (USA)
Precision Medicine In Trump Era? California Presses Own Modest Program [Xconomy] While most eyes were on the national stage, the California Initiative to Advance Precision Medicine (CIAPM) announced six “demonstration” projects last week, each to receive $1.2 million, bringing the total to eight funded projects so far.
As Trump prepares for office, Biden’s ‘moonshot’ against cancer hangs in the balance [STAT] The moonshot has faced plenty of skeptics, but Trump’s election cast the first real doubts about whether it would continue at all.
US Cancer Moonshot must strike a balance between research and prevention [Nature] Too often in health research, straightforward prevention programmes, and the social science needed to implement them correctly, are pushed aside in favour of the basic research that fills this journal.